Anti-ATG4A Antibody (2N859) is a Rabbit antibody targeting ATG4A. Anti-ATG4A Antibody (2N859) can be used in WB,IHC-P,IHC-Fr,IP,IF,ICC/IF,FCM.

IgG

2N859

Human,Mouse,Rat

1. 4% Paraformaldehyde-fixed HepG2 (H) cell; Triton X-100 at r. T. for 20 min; Antibody incubation with (ATG4A) monoclonal Antibody, unconjugated (TMAB-02919) 1:100, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green) at 37°C for 90 min, DAPI (blue) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.
2. Paraformaldehyde-fixed, paraffin embedded Mouse kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4A Monoclonal Antibody, Unconjugated (TMAB-02919) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
3. Paraformaldehyde-fixed, paraffin embedded Mouse heart; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4A Monoclonal Antibody, Unconjugated (TMAB-02919) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
4. Paraformaldehyde-fixed, paraffin embedded Rat kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4A Monoclonal Antibody, Unconjugated (TMAB-02919) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
5. Paraformaldehyde-fixed, paraffin embedded Rat heart; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4A Monoclonal Antibody, Unconjugated (TMAB-02919) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
6. Paraformaldehyde-fixed, paraffin embedded Human skeletal muscle; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4A Monoclonal Antibody, Unconjugated (TMAB-02919) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
7. Paraformaldehyde-fixed, paraffin embedded Human Brain; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4A Monoclonal Antibody, Unconjugated (TMAB-02919) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
8. Paraformaldehyde-fixed, paraffin embedded Human kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4A Monoclonal Antibody, Unconjugated (TMAB-02919) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
9. Paraformaldehyde-fixed, paraffin embedded Human heart; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4A Monoclonal Antibody, Unconjugated (TMAB-02919) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
10. Paraformaldehyde-fixed, paraffin embedded Human gastric cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4A Monoclonal Antibody, Unconjugated (TMAB-02919) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
11. 25 μg total protein per lane of various lysates (see on figure) probed with ATG4A monoclonal antibody, unconjugated (TMAB-02919) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r. T. for 60 min.

WB: 1:500-2000; IHC-P: 1:50-200; IHC-Fr: 1:50-200; IP: 1:20-50; IF: 1:50-200; ICC/IF: 1:50-200; FCM: 1:50-100

Monoclonal

A synthesized peptide: human Cysteine protease ATG4A

Human

ATG4A

Cysteine protease ATG4A

Cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes. Preferred substrate is GABARAPL2 followed by MAP1LC3A and GABARAP.